Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies 2019

Brian Dougherty's Biography

Brian Dougherty, Executive Director, Translational Genomics, Oncology IMED, AstraZeneca R&D

Brian is the Executive Director of Translational Genomics Oncology at AstraZeneca Pharmaceuticals in Boston, MA leading AstraZeneca’s cancer genomics efforts. He oversees a team of lab scientists and computational biologists applying leading-edge genomic and advanced algorithmic technologies to deliver on Precision Medicine - matching the right patient with the right drug. This includes biomarker development, patient selection and monitoring strategies, identifying new tumor drug resistance mechanisms, researching genetics-based translational hypotheses, and delivering novel cancer targets. When he was previously at Bristol-Myers Squibb, Pfizer, TIGR and Amgen, Brian led sequencing, genotyping, gene expression, high-content imaging, and functional genomics lab efforts, applying technologies to enable the discovery and development of medicines for diseases such as cancer, infectious diseases, chronic pain, and Alzheimer’s Disease.

Brian holds a B.A. from the University of Delaware, a Ph.D. from Wake Forest University Medical Center, an M.B.A from the University of New Haven, and completed a postdoctoral research fellowship in the laboratory of Nobel laureate Hamilton O. Smith at The Johns Hopkins University School of Medicine.

Brian Dougherty Image

Applying ctDNA and Other Liquid Biopsy Technologies for Oncology Translational and Clinical Research

Friday, 29 March 2019 at 09:30

Add to Calendar ▼2019-03-29 09:30:002019-03-29 10:30:00Europe/LondonApplying ctDNA and Other Liquid Biopsy Technologies for Oncology Translational and Clinical ResearchLiquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island,

For over seven years, AstraZeneca’s Translational Science Oncology group has applied NGS technologies to patient testing, particularly in the liquid biopsy space. Discussion of our experiences will include:
  • Opportunities and challenges in ctDNA testing for mutational profiling, patient selection, and patient monitoring
  • Orthogonal bench-marking study of commercial ctDNA assays
  • One finding: in current testing, most tumor-plasma discordance is due to assay technical performance, not tumor heterogeneity or clonal hematopoesis
  • Landscape of the exosomal transcriptome and some potential implications for use for cancer patient testing
  • Single cell DNA and RNA technologies
  • Testing of patient samples from hematological cancers by single cell sequencing

Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonLiquid Biopsies 2019Liquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island,